Arrowhead Pharmaceuticals Management

Management criteria checks 3/4

Arrowhead Pharmaceuticals' CEO is Chris Anzalone, appointed in Dec 2007, has a tenure of 16.42 years. total yearly compensation is $9.92M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 3% of the company’s shares, worth €80.24M. The average tenure of the management team and the board of directors is 5.9 years and 13.5 years respectively.

Key information

Chris Anzalone

Chief executive officer

US$9.9m

Total compensation

CEO salary percentage	9.1%
CEO tenure	16.4yrs
CEO ownership	3.0%
Management average tenure	5.9yrs
Board average tenure	13.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Anzalone's remuneration changed compared to Arrowhead Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$297m
Sep 30 2023	US$10m	US$903k	-US$205m
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m
Jun 30 2018	n/a	n/a	-US$54m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	n/a	n/a	-US$35m
Sep 30 2017	US$2m	US$616k	-US$34m

Compensation vs Market: Chris's total compensation ($USD9.92M) is above average for companies of similar size in the German market ($USD2.55M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Anzalone (54 yo)

16.4yrs

Tenure

US$9,918,093

Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Anzalone	CEO, President & Director	16.4yrs	US$9.92m	3% $ 80.2m
Kenneth Myszkowski	Chief Financial Officer	14.3yrs	US$3.12m	0.19% $ 5.1m
Patrick O'Brien	COO, General Counsel & Secretary	9.4yrs	US$3.31m	0.23% $ 6.2m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$3.05m	0.17% $ 4.4m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	no data	no data
Vincent Anzalone	Head of Investor Relations & VP	no data	no data	no data
Howard Lovy	Director of Communications	18.8yrs	no data	no data
Bruce Given	Chief Medical Scientist	less than a year	US$16.34m	no data
Mark Seefeld	Head of Toxicology & VP	no data	no data	no data
Tracie Oliver	Chief Commercial Officer	1.9yrs	US$2.97m	0.0073% $ 194.3k
Aaron Tan	Head of Tax	2.3yrs	no data	no data
Nadia Meshkova	VP & Treasurer	2.3yrs	no data	no data

5.9yrs

Average Tenure

59yo

Average Age

Experienced Management: HDP1's management team is seasoned and experienced (5.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Anzalone	CEO, President & Director	16.4yrs	US$9.92m	3% $ 80.2m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	no data	no data
Douglass Given	Chairman of the Board	13.5yrs	US$474.60k	0.11% $ 3.0m
Michael Perry	Independent Lead Director	12.4yrs	US$459.60k	0.074% $ 2.0m
William Waddill	Independent Director	6.3yrs	US$469.60k	0.027% $ 710.2k
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	no data	no data
Mauro Ferrari	Independent Director	13.8yrs	US$459.60k	0.037% $ 989.1k
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	no data	no data
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data

13.5yrs

Average Tenure

64yo

Average Age

Experienced Board: HDP1's board of directors are seasoned and experienced ( 13.5 years average tenure).

Arrowhead Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Chief Financial Officer recently sold €1.3m worth of stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Chief Medical Officer recently sold €518k worth of stock

Chief Financial Officer recently sold €496k worth of stock

Chairman of the Board recently sold €241k worth of stock

Recent updates

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Chief Financial Officer recently sold €1.3m worth of stock

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023)

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

New major risk - Financial position

New major risk - Share price stability

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022)

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

New minor risk - Insider selling

Chief Medical Officer recently sold €518k worth of stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New minor risk - Share price stability

Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Insider selling

Chief Financial Officer recently sold €496k worth of stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold €241k worth of stock

Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022)

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Independent Director recently sold €258k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chairman of the Board recently sold €276k worth of stock

Chief Commercial Officer James Hassard has left the company

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020)

Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Chief Commercial Officer recently sold €272k worth of stock

Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 2Q 2020)

Arrowhead Pharmaceuticals Inc. Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

New 90-day low: €54.23

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Chairman of the Board recently sold €82k worth of stock

First quarter 2021 earnings released: US$0.20 loss per share (vs US$0.028 loss in 1Q 2020)

Revenue misses expectations

New 90-day high: €70.61

Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

Chief Financial Officer recently sold €868k worth of stock

Independent Lead Director recently sold €248k worth of stock

Chairman of the Board recently sold €620k worth of stock

Independent Director recently sold €176k worth of stock

New 90-day high: €60.74